Streetbeat News

IMMX

Immix Biopharma, Inc.

https://www.immixbio.com

Industry

Biotechnology

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Open

1.61

Mkt cap

44M

Volume

57K

High

1.64

P/E Ratio

-1.92

52-wk high

7.75

Low

1.54

Div yield

N/A

52-wk low

1.26

Immix Biopharma, Inc. (NASDAQ:IMMX) has been granted the European Union Orphan Drug Designation (ODD) for NXC-201, a treatment for AL Amyloidosis. This designation offers 10 years of market exclusivity in the EU, access to centralized authorization, reduced fees, and other benefits. The U.S. prevalence of relapsed/refractory AL Amyloidosis is increasing by 12% annually, with an estimated 29,712 patients in 2023. The company believes NXC-201 could be a one-time treatment option for this condition, with a favorable tolerability profile and potential for expansion into other autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 2:41 pm

Immix Biopharma has priced a public offering of 5,535,055 shares at $2.71 each, aiming to raise approximately $15 million. The funds are intended for NXC-201 clinical trials, working capital, and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 8:38 am

Trading of Immix Biopharma shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:39 pm

Immix Biopharma shares were halted due to a circuit breaker trigger after the stock plummeted by 15.4%. This significant drop led to a temporary pause in trading to mitigate further immediate losses and allow the market to digest the information.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:34 pm

Trading of Immix Biopharma shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:33 pm

Immix Biopharma shares were halted due to a circuit breaker trigger as the stock plummeted by 10.1%. This significant drop led to a temporary pause in trading to manage volatility.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:22 pm

Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, announced its intention to offer and sell shares of its common stock in an underwritten public offering. The offering's size and terms are yet to be disclosed and are subject to market conditions. The company plans to use the net proceeds for NXC-201 clinical trials, working capital, and general corporate purposes. Titan Partners Group, LLC is the sole book-running manager for the offering.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:21 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Onconetix (ONCO) saw a 161.5% rise, while Processa Pharma (PCSA) increased by 98.04%. Acutus Medical (AFIB) and Vera Therapeutics (VERA) also saw substantial gains. Conversely, Redhill Biopharma (RDHL) and Nuwellis (NUWE) were among the notable losers, with declines of 47.6% and 15.2%, respectively. Humana (HUM) also declined by 12.06% after releasing Q4 earnings.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:31 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Virpax Pharmaceuticals (VRPX) saw a 57.8% increase, while Verrica Pharmaceuticals (VRCA) rose by 51.06%. ASLAN Pharma (ASLN), Biophytis (BPTS), Context Therapeutics (CNTX), and Immix Biopharma (IMMX) also saw gains. Conversely, Aadi Bioscience (AADI), Aileron Therapeutics (ALRN), Cingulate (CING), Vapotherm (VAPO), SenesTech (SNES), and IN8bio (INAB) experienced declines, with AADI dropping 56.5%.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:31 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. TriSalus Life Sciences (TLSI) led the gainers with a 38.3% increase, while Reneo Pharmaceuticals (RPHM) saw the largest decline, dropping 81.9%. Other notable movers included Immix Biopharma (IMMX), Codexis (CDXS), and Apellis Pharmaceuticals (APLS) among others, with varying impacts on their market capitalization.

Portfolio Pulse from Benzinga Insights

December 14, 2023 | 5:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.